PreSize Diagnostic medical device software for increased precision in advance selection of best surgical scenario for every patient at point of diagnosis

我们开发了PreSize医疗设备软件：一种新颖的临床决策支持解决方案，帮助外科医生在开始挽救生命的手术之前，通过逼真的实时模拟来计划和排练脑血管内的植入物放置。使用尖端的计算模型，我们最好地利用患者成像和设备力学来准确地预测每个患者的血管解剖中的设备行为。这使临床医生能够为每个患者选择最好的设备，减少医院/社会的并发症和手术成本。该项目将扩大/增加PreSize的能力，以支持更多患者从诊断到治疗的关键临床决策。我们将为临床医生提供前所未有的能力，并有可能从根本上改变动脉瘤的治疗途径。具体地说，我们将推进已经开创性的PreSize，以支持诊断性**CTA**扫描(用于大多数疑似动脉瘤患者的快速、廉价、微创成像)，以及PreSize目前使用的(3D)**DSA**(昂贵的侵入性成像，但质量要高得多；用于在手术过程中指导植入物的放置)。**建议的PreSize诊断**在整个护理过程中增加了Precision Medicine，而不仅仅是在手术当天，支持针对患者的治疗分层/计划，并以前所未有的技术支持帮助临床医生为手术日做好准备(提供最佳的植入物选择和最佳的手术结果)。这些技术进步最终旨在减少患者痛苦，最大限度地降低医疗成本，并优化/标准化护理。我们是一家屡获殊荣的初创企业，旨在将这项新技术引入医院。我们拥有一支由工程、软件、商业、法律和监管专家组成的强大团队，之前一直得到IUK和NIHR的支持，并得到皇家工程院的持续支持。我们的奖项包括：*NHS创新奖2017*2018年最佳医疗创业公司(WIRED)*BioMedEng创新奖2021，以表彰其‘突破性工作，导致了支持医疗干预的新技术’*IUK的‘女性创新’奖，2023**，表彰‘50位英国领先的改变游戏规则的女企业家之一’我们入选DigitalHealth.London Accelerator计划，是飞利浦医疗加速器全球6家初创企业之一。我们曾在《福布斯》、《连线》、《泰晤士报》、《金融时报》、《每日电讯报》等媒体上进行专题报道。最近，PreSize在**BBC Click**科技节目(2023年2月3日，BBC iPlayer)中被实战捕捉到。我们的目标是将牛津心跳发展成为临床决策支持工具的领先提供商，以促进英国经济及其在医疗保健领域的国际领先地位，改善所有人的医疗保健，并定义未来的医学。

We have developed PreSize medical device software: a novel clinical decision-support solution that helps surgeons plan and rehearse implant placements inside brain blood vessels with realistic, real-time simulations right before starting life-saving surgery. Using cutting-edge computational modelling, we make best use of patient imaging and device mechanics to accurately predict device behaviour inside each patient's vessel anatomy. This allows clinicians to select the best device for every patient, reducing complications and cost of surgeries for hospitals/society.This project will extend/increase PreSize's power to support crucial clinical decision-making for more patients, across their journey from diagnosis to treatment. We will provide never-before-seen capabilities to clinicians and potential for aneurysm care pathways to be radically transformed. Specifically, we will advance the already ground-breaking PreSize to support diagnostic **CTA** scans(rapid, inexpensive, minimally-invasive imaging used for most patients suspected of aneurysm) in addition to (3D)**DSA** that PreSize currently uses(expensive, invasive imaging, but of significantly higher quality; used to guide placement of implant during procedure).**Proposed PreSize Diagnostic** adds Precision Medicine throughout the care pathway instead of only on surgery day, supporting patient-specific treatment stratification/planning and helping clinicians best prepare for surgery day (accommodating best implant choices and delivering best surgical outcomes) with unprecedented technological support. These technological advancements ultimately aim to reduce patient suffering, minimise healthcare costs, and optimise/standardise care.We are an award-winning start-up created to bring this novel technology to hospitals. With a strong team of engineering, software, commercial, legal and regulatory experts, we have been previously supported by IUK and NIHR and receive ongoing support from The Royal Academy of Engineering. Our awards include:* NHS Innovation Award 2017* "Best Healthcare Start-up of 2018" (WIRED)* BioMedEng Innovation Prize 2021 for 'ground-breaking work which has led to new technologies that support medical interventions'* **IUK's 'Women in Innovation' Award 2023** for 'one of 50 of the UK's leading women entrepreneurs for game-changing ideas'We were selected for the DigitalHealth.London Accelerator programme, and were one of 6 startups selected globally by Philips Healthcare Accelerator. We have featured in the general press, e.g., Forbes, WIRED, The Times, Financial Times, The Telegraph, etc. Most recently, PreSize was captured in action in the **BBC Click** tech show (February 3, 2023, BBC iPlayer).We aim to grow Oxford Heartbeat to become the leading provider of clinical decision-support tools, to boost the UK economy and its international leadership in healthcare, to improve healthcare for all, and define the medicine of tomorrow.